© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
DexCom, Inc. (DXCM) stock surged +0.41%, trading at $61.82 on NASDAQ, up from the previous close of $61.57. The stock opened at $61.12, fluctuating between $61.05 and $61.90 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Apr 23, 2026 | 63.09 | 63.78 | 61.90 | 62.70 | 2.5M |
| Apr 22, 2026 | 63.16 | 63.87 | 62.51 | 63.41 | 2.67M |
| Apr 21, 2026 | 64.87 | 65.00 | 62.41 | 62.60 | 4.08M |
| Apr 20, 2026 | 63.57 | 65.29 | 63.34 | 64.62 | 3.74M |
| Apr 17, 2026 | 62.43 | 64.09 | 61.90 | 63.98 | 7.28M |
| Apr 16, 2026 | 61.29 | 63.89 | 60.82 | 61.23 | 5.74M |
| Apr 14, 2026 | 62.69 | 63.70 | 62.00 | 62.95 | 4.72M |
| Apr 13, 2026 | 63.99 | 64.03 | 61.64 | 63.12 | 5.7M |
| Apr 10, 2026 | 65.90 | 66.14 | 63.61 | 64.02 | 2.05M |
| Apr 09, 2026 | 65.39 | 66.44 | 64.40 | 65.68 | 3.76M |
| Apr 08, 2026 | 65.01 | 65.87 | 64.86 | 65.80 | 2.81M |
| Apr 07, 2026 | 63.10 | 64.28 | 62.58 | 63.11 | 3.55M |
| Apr 06, 2026 | 62.22 | 63.30 | 62.10 | 63.21 | 2.88M |
| Apr 02, 2026 | 61.60 | 62.86 | 60.57 | 62.22 | 2.41M |
| Apr 01, 2026 | 62.80 | 63.67 | 61.91 | 62.37 | 3.36M |
| Mar 31, 2026 | 62.77 | 63.68 | 61.96 | 62.80 | 3.94M |
| Mar 30, 2026 | 62.35 | 63.25 | 61.62 | 61.90 | 3.95M |
| Mar 27, 2026 | 65.91 | 65.91 | 61.99 | 62.25 | 4.26M |
| Mar 25, 2026 | 67.22 | 68.09 | 65.54 | 66.84 | 2.92M |
| Mar 24, 2026 | 66.31 | 66.94 | 65.10 | 66.60 | 3.81M |
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
| Employees | 10200 |
| Beta | 1.56 |
| Sales or Revenue | $3.62B |
| 5Y Sales Change% | 2.209% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Devices |